Founded in 1993 through brothers Tom and David Gardner, The Motley Fool is helping millions of people gain monetary freedom through our website, podcasts, books, newspaper columns, radio screens and high-level investment services.
Leaders in the COVID-19 vaccine career have surnames in the United States. Millions of Americans get vaccines developed through Pfizer and BioNTech, Moderna and Johnson.
But there are also other vaccines in development. In this Motley Fool Live video recorded on March 3, Fool. com participants Keith Speights and Brian Orelli talk about whether two stocks of expired COVID vaccines can still be winners.
Keith Speights: All right, let’s get to know about some of the corporations. It’s not an exhaustive list, but let’s get back to some of the corporations that aren’t the most sensitive on the list that are about to arrive as candidates for the COVID 19 vaccine. going to the technique one by one. Let’s see if any of those corporations have a realistic chance of placing a major player in the US COVID-19 vaccine markets. But it’s not the first time Or Europe and what movements can be serious through investors.
Let me start by talking about a company called CureVac (NASDAQ: CVAC), the key is CVAC, they’re presenting a COVID-19 Brian candidate vaccine, what investors know about CureVac, is this an action they have in their Radar?
Brian Orelli: It is an mNR-based vaccine like Moderna and Pfizer and are in phase 2b/3 of clinical trials. They have presented a continuous connection with the EMA, the European regulator, and are partnering with Bayer for development. reached an agreement with the EU to deliver 405 million doses.
A fairly giant company with a market capitalization of around $17 billion. It’s a bigger biotechnology company than, say, some of the smaller ones we’ll probably communicate with. Probably the ones that are left and that we don’t communicate about today. , it probably is and the others are. I’d say it’s the mature maximum of the five and the promising maximum.
Speights: Especially because they have a big challenge with the European Union. When you already have an order of origin of more than 400 million doses. Assuming everything goes well with their overdue evidence, they deserve to be on their way to winning a giant amount. cash very soon, right?
Orelli: Yes.
Speights: This is a factor investors at least keep their eyes on. Let’s learn about a much smaller biotechnology inventory that comes with a COVID-19 Arcturus Therapeutics (NASDAQ: ARCT) candidate vaccine. The price ticket there is ARCT. Brian, what do investors know about Arcturus?
Orelli: They had effectiveness disorders at first, in phase two of clinical trials, I mean moving to phase three, it’s a single-dose mNS vaccine, they have origin agreements with Singapore and Israel and a market capitalization of $1 billion.
I’m involved in efficiency. When you see disorders with the first know-how when you look at antibody levels, this would possibly result in inadequate antibody production for canopy patients exposed to coronavirus.
Speights: If you move on to phase 3 as you expect to do in this quarter, that will give us a revealing signal, isn’t it possible?This will show whether it is effective or not and, if so, those source agreements. are aligned, not massive source agreements. We are talking about Singapore and Israel, however, the market capitalization is still quite small. It’s an action, I guess if they succeed, they can just increase. But as you say Brian, the chances of a good fortune isn’t so wonderful right now.
Orelli: I literally worry when you run phase 1 knowledge disorders that don’t seem as smart as some of the other Phase 1 corporations and it’s hard to compare knowledge from one phase to another, however, antibodies are antibodies that run the same tests and you measure antibody grades and have particularly low grades of antibodies that probably haven’t translated into less effectiveness when you’re testing whether it protects to someone from coVID progression 19.